CD105-Targeting Polypeptides for Precision Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective methods and compositions that target CD105 and CD105+ tumors for cancer treatment, as existing technologies have limitations in addressing these specific targets.
Innovation Solution
The development of engineered polypeptides, such as chimeric antigen receptors (CARs) and T-cell receptors (TCRs), that specifically bind to CD105, which can be expressed on the surface of immune cells to target CD105+ cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional cancer treatment methods are used, then treatment coverage is broad, but specificity to CD105+ tumors is insufficient
Solution Approach 1:
The treatment approach is segmented into CD105-specific targeted therapy versus conventional broad-spectrum therapy. The patent applies segmentation by developing CARs and TCRs that specifically target CD105+ tumors, separating the patient population into those who benefit from targeted precision therapy versus those who require conventional broad-spectrum approaches.
Solution Approach 2:
The invention changes the parameter of target specificity from non-specific to CD105-specific. By modifying the receptor specificity parameter in CARs and TCRs, the treatment achieves high precision targeting of CD105+ tumors while maintaining effectiveness through parameter optimization rather than broad coverage.
2Measurement precision
If CD105-targeting polypeptides are developed, then treatment specificity is improved, but development complexity increases
Solution Approach 1:
The patent applies universality by developing a platform approach where CD105-specific CARs and TCRs can be generated using standardized methodologies. The same engineering framework can be applied to different CD105+ tumor types, making the complex polypeptide development process reusable and less complex through standardization.
Solution Approach 2:
The invention uses intermediary elements such as standardized CAR and TCR platforms that mediate between the complexity of polypeptide engineering and the need for specific target recognition. These intermediary frameworks simplify the development process while maintaining high target specificity through modular design.
3Reliability
If engineered polypeptides like CARs and TCRs are used, then tumor targeting capability is enhanced, but manufacturing and implementation complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-characterizing and pre-engineering CAR and TCR platforms before clinical application. Standardized protocols for generating CD105-specific receptors are established in advance, reducing the complexity of manufacturing and implementation during actual tumor treatment.
Solution Approach 2:
The invention implements self-service through autonomous CAR and TCR generation systems that can be rapidly produced and deployed. The platforms are designed to be self-sufficient, reducing the need for complex external manufacturing processes and enabling streamlined implementation from laboratory to clinical setting.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These CD105-targeting polypeptides enable immune cells to specifically recognize and kill CD105+ cancer cells, providing a potential therapeutic approach for cancer treatment.
Implementation Method 1
engineered polypeptides such as chimeric antigen receptors (CARs) and the like... comprising a CD105-binding region
Data Source
AI summary
Embodiments of the present disclosure include methods and compositions related to CD105-targeting polypeptides. In some aspects, disclosed are chimeric receptors engineered to bind to CD105. Cells (e.g., NK cells, T-cells) expressing CD105-targeting peptides are described. Also described are therapeutic methods using polypeptides of the disclosure.